Thank everybody. you, Rob, afternoon, and good
the this webcast. review slide accompanies I'd to your that turn I IMPALA the like deck data, to As attention
patients So with, of daily study by two reminding micrograms will was where period every active a design a period dosing got the and a you included treatment comparing that to to followed arm begin This daily arms, alternating other open-label XX week, start dosing XXX arms a XX-week I intermittent, regimen. placebo. placebo-controlled for with all these the all of by active treatment weeks,
were we the The end which point had or in open-label of A-aDOX an safety is up subjects baseline an gradient, enroll was an extension study oxygen short. call the alternating the regimen study primary the for allowed to to from three to to on in allows changed IMPALA-X, of or subset continue that option A arterial-alveolar years. into patients what
distance, as X-minute lavage, well or to this as key Secondary lung study. time walk end whole Questionnaire, rescue treatment allowed SGRQ, the was as points George’s during which a St. Respiratory included
to to were all analysis the point then assessment. end statistical The subject have threshold, would continued predefined which points, included, the was simultaneously. analyzed sequence analysis the primary over secondary that meeting statistical significance the first, that end And
statistically claimed Now the did end not analysis subsequent cannot formally primary meet because points, to all significant. we the be statistically be
present plan, communication, will that sequence data reviewing statistical of of presentation, will in use Also, sequence the I presentation, this we of for the term in this the the data instead disease in However, ease in the process. the of regardless. analysis
caused is and from starting which clinical the excess to gas by is the surfactant over pathology, means outcomes. the to then then the over that in excess the of disease surfactant, exchange the and which lungs, moving impaired pathophysiology, So
Before summary safety. covering brief efficacy data, of the the a
As all the that's of as we whether you can events different the numbers events, or serious right. picture the adverse respiratory just had almost treatment events. indistinguishable the a arms, events adverse graph, in system see from adverse similar between shown on adverse And
and no we of and rate, evidence the observed the antibodies observed for what as attested higher, any a laboratory very a arm. percent little of no in active above changes a had the anti-drug X%, dropout the patients in in about over arms the We values forming We anti-GM-CSF placebo only significant disease-causing antibodies. low clinically had is safety, and few in
pathology. the So to begin with, on
from in and X represents significant score surfactant-filled a disease XX a cloudy using baseline aPAP shows called highly would So ground CT a where dosing good XX, is results and excess, of way fully a scan. lung, visualize clear a and opacification represent is What to scan X this is improvement placebo. the a statistically XX arm to the compared through normal week a high-resolution is what surfactant graph here a continuous This dose-frequency-dependent glass CT whereas is to measure. we lung. This see as score air-filled
out demonstrate lungs. excess So words, of are the in able we that to we other here surfactant remove the
various our blood. disease almost way biomarkers only the that the range exception were these a much dose-dependent to pathology in didn't significant, biomarker impacts broad And from of there. so the improvement lung-derived, surprising we all a statistically again, see surfactant is not showed with effect through is, not that are fact, of is Another in of that an dosage perhaps measured of a the in where the A, which study, protein we biomarkers, continuous consistent assess in arm, biomarker
together, What clear A-aDOX primary the that. and about millimeters same overall caused effect was test suggest the us was we placebo we taken the was in by overload? and this impaired fail did what was the CT the the to in these about So which was point assess effect, in gas pathophysiology, And because The does that scans, point. How end pathology us particular, studies. then biomarkers to extent time XX shown this based surprising, for the statistical reversal translate patients. over surfactant the a of the of expected is had improvement into that open-label really exchange was here do mercury, of consistent as of end prior placebo on see the though, this disease
used some using found by analyzed happened, the and So during patients baseline from supplemental as we And for And the have in the during dug were rate long the was same to arterial allowed all to baseline. unable what treatment change as testing. of the or on the unusual data sampling. oxygen when who little time supplemental on we this points their patients unwilling severe flow the was expected as effect values this deeper we protocol parameter this into discontinue had blood following oxygen
And tight graph one the correlate moves here, are as where in over exactly be the the Now the And because a input entirety. of right concentrations here supposed the tightly this correlation an very which having measure, inputs. between subjects values. with in added level curve they're the oxygen shown color oxygen and are calculated A-aDOX, blood correlation on oxygen shows is supplemental low -- oxygen as the oxygen actually who right, on increasing the the A-aDOX to to here its
in However, shown is this to nowhere where be. supposed is B, patient red, near patient
patients suggests that on oxygen reliable. And necessarily not the so testing this is
-- testing slide during revised the to results set. the presented the So on exclude test accordingly the shown QX to decided with guideline, The according -- test shown revised who primary of in tested is been statistical the supplemental -- is analysis, alongside then we patients primary all following analysis oxygen had here. this ICH and a
And effect same, result observed a supplemental dose and that all continuous during between outlier statistically is we that the the or gross effect What placebo more or treatment oxygen. regardless tested the exclude and placebo. of patients one less were now bigger is is this a we significant whether reduced
into impact Now test gas the test that an the removal a exchange capacity breathing the is diffuses diffusion the based for from it another gas test in is DLCO, A-aDOX in given of circulation patient's and way This and the gas independent a time. much analyzing to from is the carbon on surfactant how test then lungs that monoxide. of mechanistically
So see consistently DLCO we from with point placebo. here, to improvement expect highly the point and is continuous that effect statistically treatment in between arm time percent the predicted. a time certainly And dosing we to see that do significant
their in together, which removing that demonstration GM-CSF of surfactant exchange taken revised DLCO, we analysis the using the especially gas are exchange, patients this A-aDOX in translates and meaningful the gas independent PAP represents that measures do into a set So improvement status. of believe with
that different does considered what is score patient-reported how X outcomes? that using in outcomes different the into So analysis clinical A starting thresholds tool X this lower key SGRQ, lung odds to ratios measured X from of in threshold secondary rates St. George's we X X about better points. chronic statistically the we points health up Respiratory points, the effect in from end to points we the representing treatment And was One to lower all the we translate improvements further, status. such of thresholds, an of was Questionnaire. observed significant analyzing arms in in other with what represents response, observed almost clinically X responder as with and impressive all COPD. meaningful these placebo, statistically And quite disease for threshold significant. the response conducted SGRQ X-point both in In and points, again, highly compared improvement ranging
evaluated these the as with observed different we've activities, which tool, being all this statistically of for significant activity impacts patient's of own. Further, across in well general SGRQ, as symptoms. the analyzing improvements And daily their and it a life consists respiratory domains on on of the impact we domains
a we taken believe So represents together, robust result SGRQ. very this on the
dependency frequency X-minute notable favor very also continuous what the be far. there appears who of well. arm be that a is trend able walk distance showed in not the secondary dosing to are other the end as to Of patients It's in a to walk PAP tendency old, points, dose and quite
that to being treatment the as result to the possible a approach therefore, of of a is terms not this of estimated end contributed with effect, in to and we this had statistical point. So beforehand, as have it bit ceiling contributed may and potentially quite effect our started large test we failing
arms. a Furthermore, use trend treatment, as in of the in terms had other that notably treatment of lavage whole both favor of was treatments, a also lung we rescue used
the we we due significance However, the the But lung to low reach short and point,. months, on this ratios rate to how of forward active arms longer open-label treatment of count and of And failed the encouraging. this procedure the treatment our event were end statistical much part duration. look relatively patients progressed to period placebo between for this when lavages X a has exposed certainly study very quite in to have seeing been
overall, finally, time. lung what disease, presenting to a chronic a are values measure the so here of over And happened as cumulative hemoglobin we
air, here, hemoglobin And time statistically So overall compensatory increase and increasing hemoglobin point the back normal similar upon we're a in thin likewise heart the reverses the and and hypoxia chronic to the compared a tends to the significant to arm same chronic the a hemoglobin and person in increase in to as exactly this to consistent a going disease being for in response as mountains little treatment seeing mechanism the disease, normal. in a to return to reduction sea almost placebo. level, point-to-time then happen, hemoglobin lung back
So with over improvement overall the with time of patients in in opinion, captures our other fits nicely disease and our product. processes the the reversal very these this
health In of the So elements. points pathology, use with in trended the improved we the physiology, established and of that either at disease end or favor summary, therapies and different many have different function the significantly statistically rescue looking drug. status
strength And therefore, the lung -- outcomes, antibodies directly shown The In perfect and therapy evidence as this have cause totality, of treatment in is lung fit is the pathology study, clinical improvement we off-label drug, disease. onset impactful. of of and for or into lungs known the biology that a this the anti well GM-CSF studies and be as different pathophysiology systemic the root our all so rescue reversal through lung of of The prior in adaptation give aPAP. known cause these, reversal treatments, the to to all frequency-dependent, -- fact, this anti-GM-CSF And a this this contributing disease, GM-CSF practice, mechanism dataset. of supplemental the known of from starts of using further reduction of the mechanism. to our suggests being really, dose open-label and to chronic clinical are
study. now We on that have well the drug our on do prior works, KOL based as based strong both as the IMPALA consensus studies
way now regulatory And initiating the discussions are figure of just data out that discussions with includes to product. so our I've given forward the we in totality EMA the outlined, working coming with best for This agencies the with and continuing the months. the FDA
which meantime, are programs In the are on which Molgradex who NTM to by exploratory treatment of next mycobacteria, ENCORE provide earlier-stage OPTIMA, initiated study, targeted we in line we're in quarter with X progressing to to subjects. advance. In infection. program The still is approximately or studies, the results other first this focuses for conducting evaluating expect nontuberculous year, with CF the continues cystic in enroll people we we a of Molgradex our living continue our CF, guidance, or not enrollment top which clinical XX impacted fibrosis, lung people with second year. our and line of earlier
been And which fully a year study adult move aureus, methicillin-resistant the in is program investigational on the lastly, The let's population III enrolled AeroVanc, CF. AeroVanc MRSA with has treatment AVAIL for to Phase lung pivotal people or of our about in infection for now. Staph
between reach left out Therefore, X, target years and our As go until just that age, enrollment total target. population, of of the primary of XX a XXX. of younger there's to has we patients the enrolled XX November XXX is analysis patients X
study rate XX% for the subjects the as explained and before, screening in is enroll candidates And the have we time are who range between very sick. screen randomization. the occur often to to are pulmonary continue failure of As exacerbations
Additionally, screening, at criteria failed the required of lung time many meet the the study. to function for subjects
reaffirm this the or key to expected study. the with quarters, completion top line for our half this we early in later a hard Given I last XXXX, are of seen to that working complete the over XXXX. important we've of rate us, that current we of -- program enrollment year this guidance year that underscore first enrollment enrollment is results like would or and in
therefore, like of also addressing in issues, modulator a CF. to these priority and advances that despite the key new acknowledge to Foundation new from remains for the treatments, that CF would as our CFTR infection development. well I KOLs management high in suggests the chronic feedback inflammation continue as challenges And drug managing be
will over I'll now the you a with financial call provide Dave, who turn update. to
